Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test
On Sept. 10, 2025, Exact Sciences announced the launch of the Cancerguard™ test, a new multi-cancer early detection…
AI can improve ovarian cancer diagnoses
On Jan. 2, 2025, an international study led by researchers at Karolinska Institutet in Sweden shows that AI-based…
Oxford Researchers Received Funding to create world’s first ovarian cancer prevention vaccine
On Oct. 4, 2024, researchers from Oxford university announced they had been awarded funding from Cancer Research UK…
Breast and ovarian cancer linked to thousands of gene variants
On Sept. 18, 2024, researchers from the Wellcome Sanger Institute and their collaborators reported that they had identified…
Biotechnology | Disease | Environmental | EPA | Therapeutics
U.S. Environmental Protection Agency finalized ban on ongoing uses of asbestos to protect people from cancer
On Mar. 18, 2024, the U.S. Environmental Protection Agency (EPA) announced a final rule to prohibit ongoing uses…
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics | Women's Health
FDA Cleared 23andMe improved BRCA report for communities underrepresented in genetic testing
On Aug. 31, 2023, the U.S. Food and Drug Administration (FDA) cleared for marketing the updated 23andMe Personal…
Biotechnology | Diagnostics | Non-Profit Research | Oncology | Therapeutics | Vaccine | Women's Health
CPRIT approved $12 million to bring top-flight cancer researchers to Lone Star State
On Nov. 16, 2022, the Cancer Prevention and Research Institute of Texas (CPRIT) approved $12 million in recruitment…
Biotechnology | Diagnostics | Disease | Oncology | Vaccine | Women's Health
Anixa Biosciences Announced Publication of Peer-Reviewed Journal Article Highlighting Ovarian Cancer Vaccine Technology
On Jun. 21, 2022, Anixa Biosciences announced the publication of a peer-reviewed journal article in Clinical and Experimental…
McGill University Professor William Foulkes awarded 2020 Wilder-Penfield Prize for research in the genetics of breast and ovarian cancer
On Nov. 4, 2020, McGill University Professor William Foulkes awarded 2020 Wilder-Penfield Prize for research in the genetics…
AIM ImmunoTech announced NCI award of $14.54 million to study Ampligen as part of five Roswell Park-led chemokine modulation clinical trials in melanoma, colorectal and ovarian cancers
On Apr. 6, 2020, the National Cancer Institute awarded of $14.54 million to Roswell Park Comprehensive Cancer Center…
TESARO was acquired by GSK for $5.1 billion
On Jan. 22, 2019, GlaxoSmithKline acquired TESARO based in Waltham, Massachusetts, for an aggregate cash consideration of approximately…
Masonic Cancer Center researchers received $1.4 million in grants for ovarian cancer research
On Jan. 18, 2019, Masonic Cancer Center researchers received $1.4 million in grants for ovarian cancer research from…
FDA authorized direct-to-consumer test that reports three mutations in the BRCA breast cancer genes
On Mar. 6, 2018, the U.S. Food and Drug Administration authorized 23andMe’s Personal Genome Service Genetic Health Risk…
World Ovarian Cancer Day was established
On May 8, 2013, was the first World Ovarian Cancer Day. On this day, ovarian cancer organizations from…
Biotechnology | Diagnostics | Disease | Genomics | NIH | Oncology | Therapeutics | Women's Health
NIH announced two integral components of the Cancer Genome Atlas Pilot Project
On Oct. 16, 2006, the Cancer Genome Atlas program, created by National Cancer Institute and the National Human…
Eli Lilly and Company’s Gemzar was approved for use in the treatment of women living with recurrent ovarian cancer
On Jul. 17, 2006, Eli Lilly and Company’s Gemzar was approved by the U.S. Food and Drug Administration (FDA) for…
Data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial was announced
On Jun. 5, 2003, data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial gave fresh insight…
NCI funded trial showed postmenopausal women who used estrogen replacement therapy were at higher risk of developing ovarian cancer
On Jul. 17, 2002, a National Cancer Institute funded trial showed that postmenopausal women who used estrogen replacement…
Scientists from NCI and FDA reported that patterns of proteins found in patients’ serum may reflect the presence of ovarian cancer
On Feb. 7, 2002, scientists from the National Cancer Institute (NCI) and the Food and Drug Administration (FDA)…
Topotecan (Hycamptin) was approved by the FDA for the treatment of metastatic ovarian cancer
On Jul. 1, 1996, topotecan (Hycamptin), the first of a class of drugs that interferes with the enzyme…
Biotechnology | Cloning | Diagnostics | Disease | Genomics | Oncology | Therapeutics | Women's Health
BRCA1 breast cancer-associated gene was identified by positional cloning methods
On Oct. 7, 1994, a strong candidate for the 17q-linked BRCA1 gene, which influences susceptibility to breast and…
Biotechnology | Diagnostics | Genomics | Non-Profit Research | Oncology | Therapeutics | Women's Health
The first breast cancer gene was discovered
In 1994, Mary-Claire King, PhD, a University of Washington professor of genome sciences and medicine, discovered the “breast…
Biotechnology | Clinical Research | Diagnostics | Oncology | Radiology | Therapeutics | Women's Health
The Prostate, Lung, Colorectal, and Ovarian trial began recruiting 148,000 men and women, ages 55-74
In 1993, the Prostate, Lung, Colorectal, and Ovarian trial was launched. The trial was designed to determine whether…
Washington University School of Medicine announced as a participating site for the prostate, lung, colorectal, and ovarian cancers (PLCO study)
In 1993, the Washington University School of Medicine announced that it was a participating site for the prostate,…
Biotechnology | Disease | FDA | Forestry | Oncology | Therapeutics | Women's Health
Taxol (paclitaxel) approved by the FDA for the treatment of ovarian cancer that has failed other therapy
On Dec. 18, 1992, Taxol (paclitaxel), an anticancer drug extracted from the bark of the Pacific yew, received…
Pacific Health Research Institute was awarded the multi-center ‘Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial’
In 1992, the National Cancer Institute (NCI) awarded the Pacific Health Research Institute its largest and most enduring…
FDA | Oncology | Therapeutics
Carboplatin, a drug related to cisplatin, was approved by the Food and Drug Administration
On Mar. 3, 1989, carboplatin (Paraplatin), a drug related to cisplatin, was approved by the U.S. Food and…
Bristol-Myers’ PARAPLATIN (carboplatin) was approved for the treatment of recurrent ovarian cancer
On Mar. 3, 1989, the U.S. Food and Drug Administration (FDA) approved Bristol-Myers’ PARAPLATIN (carboplatin) for the treatment…
Biology | Diagnostics | Disease | FDA | Life Science History | Non-Profit Research | Oncology | Therapeutics
FDA approved Cisplatin, a platinum-containing anticancer compound
On Dec. 19, 1978, the U.S. Food and Drug Administration (FDA) approved cisplatin (Platinol) for use in combination…
Biology | Diagnostics | Disease | Life Science History | Non-Profit Research | Oncology | Therapeutics
Cisplatin, a platinum-containing anticancer compound with unique biologic effects, entered clinical trials
In 1970, Cisplatin, a platinum-containing anticancer compound with unique biologic effects, entered clinical trials. On Dec. 19, 1978,…